BioCentury
ARTICLE | Clinical News

REGN begins Axokine Phase III

July 31, 2001 7:00 AM UTC

REGN began a 2,000-patient U.S. double-blind, placebo-controlled Phase III trial of Axokine for the treatment of obesity. Patients will receive daily subcutaneous self-injections of Axokine or placebo at 1 ug/kg for 12 months followed by a 12-month open label safety extension phase during which all patients will receive Axokine. Axokine is a modified ciliary neurotrophic factor ( CNTF) that activates leptin-like pathways in the hypothalamus, suppressing appetite. ...